Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olfml3 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Abologix
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Olfml3 monoclonal antibody is an experimental therapeutic being developed by Abologix to treat various forms of cancer by inhibiting tumor-associated angiogenesis. The antibody targets Olfactomedin-like protein 3 (Olfml3), a secreted glycoprotein that is highly expressed in the tumor microenvironment and plays a pivotal role in promoting endothelial cell migration and the formation of new blood vessels. By binding to and neutralizing Olfml3, the antibody aims to disrupt the vascular supply to tumors, thereby inhibiting their growth and potential for metastasis. This program represents a targeted approach to anti-angiogenic therapy, specifically focusing on a target that is overexpressed in several solid tumors. It is currently in the preclinical stage of development.
- Other names
- anti-Olfml3 mAbanti-Olfml-3 mAbanti-Olfml 3 mAbOlfactomedin-like protein 3 monoclonal antibodyAbologix Olfml3 antibody
02
Targets
OLFML3
Beyond the preview
Go deeper on Olfml3 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Olfml3 monoclonal antibody.